written on 25.03.2014

Priority Review Voucher Accompanies FDA Approval of Impavido for Leishmaniasis


FDA approval of Impavido (miltefosine) to treat a tropical parasitic infection rare in the US has also earned Knight Therapeutics, Inc, a priority review voucher – the fourth-ever granted by the FDA. Knight is a spin-off of Paladin Labs Inc, the company that filed for Impavido approval. Knight formed in February when Endo Health Solutions […]